⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL27304002 | 0.87 | — | — | |
| SCHEMBL472871 | 0.87 | — | — | |
| Acetone SCHEMBL27433165 | 0.86 | CYP3A4 (0.31) | — | |
| SCHEMBL27858829 | 0.85 | — | — | |
| SCHEMBL27444047 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL11048878 | 0.85 | — | — | |
| Acetic Acid SCHEMBL28157557 | 0.84 | CYP3A4 (0.34) | — | |
| Benzene SCHEMBL28446162 | 0.82 | — | — | |
| Methylamine SCHEMBL27476913 | 0.82 | — | — | |
| Acetamide SCHEMBL28790430 | 0.82 | LMNA (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3914249-B1 | SELECTIVE GLUCOCORTICOID RECEPTOR MODIFIERS FOR TREATING IMPAIRED SKIN WOUND HEALING | AKRIBES BIOMEDICAL GMBH (AT) | 2024-05-01 | — | — | EP | disclosed |
| US-20220047602-A1 | SELECTIVE GLUCOCORTICOID RECEPTOR MODIFIERS FOR TREATING IMPAIRED SKIN WOUND HEALING | AKRIBES BIOMEDICAL GMBH (AT) | 2022-02-17 | — | — | US | disclosed |
| EP-3914249-A1 | SELECTIVE GLUCOCORTICOID RECEPTOR MODIFIERS FOR TREATING IMPAIRED SKIN WOUND HEALING | Akribes Biomedical GmbH (AT) | 2021-12-01 | — | — | EP | disclosed |
| CN-113382730-A | Selective glucocorticoid receptor modifiers for treatment of impaired skin wound healing | 阿克里斯生物医药有限公司 | 2021-09-10 | — | — | CN | disclosed |
| WO-2020152193-A1 | SELECTIVE GLUCOCORTICOID RECEPTOR MODIFIERS FOR TREATING IMPAIRED SKIN WOUND HEALING | AKRIBES BIOMEDICAL GMBH (AT) | 2020-07-30 | — | — | WO | disclosed |
| US-RE47047-E1 | 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents | ASTRAZENECA AB (SE) | 2018-09-18 | — | — | US | disclosed |
| US-8680117-B2 | 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents | BAYER SCHERING PHARMA AG (DE) | 2014-03-25 | — | — | US | disclosed |
| US-8394958-B2 | 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents | Bayer Pharma AG (DE) | 2013-03-12 | — | — | US | disclosed |
| US-20130005766-A1 | 5-[(3,3,3-TRIFLUORO-2-HYDROXY-1-ARYLPROPYL)AMINO]-1H-QUINOLIN-2-ONES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | Bayer Pharma AG (DE) | 2013-01-03 | — | — | US | disclosed |
| EP-2234979-A1 | 5-Ý(3,3,3-TRIFLUORO-2-HYDROXY-1-ARYLPROPYL)AMINO¨-1H-QUINOLIN-2-ONES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-10-06 | — | — | EP | disclosed |
| WO-2010049073-A1 | 1,1,1-TRIFLUORO-3-AMINO-3-HETEROARYL-2-PROPANOLES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-06 | — | — | WO | disclosed |
| EP-2149558-A1 | 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino-1-arylquinolin-2-ones, a process for their production and their use as anti-inflammatory agents | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-02-03 | — | — | EP | disclosed |
| WO-2010009814-A1 | 5-[ (3,3,3-TRIFLUORO-2-HYDROXY-1-ARYLPROPYL) AMINO]-1-ARYLQUINOLIN-2-ONES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-01-28 | — | — | WO | disclosed |
| US-20100016338-A1 | 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1-arylquinolin-2-ones, a Process for their Production and their Use as Anti-inflammatory Agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-01-21 | — | — | US | disclosed |
| WO-2009065503-A1 | 5-[(3,3,3-TRIFLUORO-2-HYDROXY-1-ARYLPROPYL)AMINO]-1H-QUINOLIN-2-ONES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-05-28 | — | — | WO | disclosed |
| US-20090137564-A1 | 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, A Process for Their Production and Their Use as Anti-inflammatory Agents | ASTRAZENECA AB (SE) | 2009-05-28 | — | — | US | disclosed |
| EP-2062880-A1 | 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-05-27 | — | — | EP | disclosed |